Free tool
FAERS Monitor: Romvimza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219304 or its brand name (Romvimza, Vimseltinib). Reports on generic versions are filed under their own applications.
Reports
549
Serious
85
15% of reports
Hospitalization
21
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue136
- swelling face69
- pruritus63
- periorbital swelling60
- peripheral swelling51
- product use issue45
- arthralgia42
- nausea42
- rash42
- eye swelling40
- headache39
- product dose omission issue34
- hepatic enzyme increased32
- asthenia30
- pain28
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 2 |
| 2022 | 1 |
| 2025 | 313 |
| 2026 | 233 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,610 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| periorbital swellingSignal | 60 | 410.9 | 323.1 | 23,876 |
| eye swellingSignal | 40 | 41.2 | 30.6 | 1,531 |
| swelling faceSignal | 69 | 40.6 | 32.6 | 2,634 |
| hepatic enzyme increasedSignal | 32 | 18.0 | 12.9 | 498 |
| peripheral swellingSignal | 51 | 12.7 | 9.8 | 541 |
| product use issueSignal | 45 | 9.2 | 6.9 | 322 |
| fatigueSignal | 136 | 6.7 | 5.8 | 678 |
| pruritusSignal | 63 | 6.3 | 5.0 | 280 |
| product dose omission issueSignal | 34 | 4.4 | 3.2 | 88 |
| arthralgiaSignal | 42 | 3.9 | 2.9 | 88 |
| rashSignal | 42 | 3.7 | 2.8 | 81 |
| astheniaSignal | 30 | 3.1 | 2.2 | 40 |
| headacheSignal | 39 | 2.4 | 1.8 | 31 |
| nauseaSignal | 42 | 2.0 | 1.5 | 22 |
| pain | 28 | 1.7 | 1.2 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.